Vaccine Manufacture and Supply – News and Features

The Phase I/II, two cohort, open label clinical trial in metastatic melanoma opens at Washington University, St. Louis, Missouri.

Trial could generate future alternative treatment for multiple myeloma.

Eden Biodesign Ltd. today announced the execution of a non-exclusive Vendor Network Agreement with Crucell, under which Eden Biodesign has become a pre-approved authorized provider of process development and cGMP manufacturing services using Crucell’s proprietary PER.C6® cell line technology. Under the terms of the agreement Eden Biodesign will be able to offer its services to Crucell’s PER.C6® licensees in the field of vaccines and gene therapy.

IDT, a global integrated contract manufacturer of vaccines and biopharmaceuticals, has introduced plans to expand its Vaccine Capacity and Workforce.

CEVEC Pharmaceuticals has announced that CAP cells produce high virus titers upon infection with influenza strains.

The dossier, containing information on the manufacture and safety of albucult, can help support the medical devices and drug formulation applications.

The Company plans to feature its range of regulatory compliant, recombinant and animal-free products and technologies at the annual conference.

Lonza expands its custom service platform to viral vaccines and gene therapy vectors.

A first-of-a-kind, plant-based vaccine factory, takes advantage of plant viral vector technology developed by Fraunhofer CMB for the biopharmaceutical company iBio.

Expansion includes the centralized distribution of the H1N1 flu vaccine to as many as 90,000 sites across the U.S.